Sharif Medical and Dental College, Lahore, Pakistan.
Senior Registrar Rawalpindi Institute of Cardiology, Rawalpindi, Pakistan.
PLoS One. 2020 Jan 17;15(1):e0225077. doi: 10.1371/journal.pone.0225077. eCollection 2020.
The data on infective endocarditis after transcatheter aortic valve implantation (TAVI) is scarce and limited to case reports and case series in the literature. It is the need of the hour to analyze the available data on post-TAVI infective endocarditis from the available literature. The objectives of this systematic review were to evaluate the incidence of infective endocarditis after transcatheter aortic valve implantation, its microbiological profile and clinical outcomes. It will help us to improve the antibiotic prophylaxis strategies and treatment options for infective endocarditis in the context of TAVI.
EMBASE, Medline and the CENTRAL trials registry of the Cochrane Collaboration were searched for articles on infective endocarditis in post-TAVI patients till October 2018. Eleven articles were included in the systematic review. The outcomes assessed werethe incidence of infective endocarditis, its microbiological profile andclinical outcomes including major adverse cardiac event (MACE), net adverse clinical event (NACE), surgical intervention and valve-in-valve procedure.
The incidence of infective endocarditis varied from 0%-14.3% in the included studies, the mean was3.25%. The average duration of follow-up was 474 days (1.3 years). Enterococci were the most common causative organism isolated from 25.9% of cases followed by Staphylococcus aureus (16.1%) and coagulase-negative Staphylococcus species (14.7%). The mean in-hospital mortality and mortality at follow-up was 29.5% and 29.9%, respectively. The cumulative incidence of heart failure, stroke and major bleeding were 37.1%, 5.3% and 11.3%,respectively. Only a single study by Martinez-Selles et al. reported arrhythmias in 20% cases. The septic shock occurred in 10% and 27.7% post-TAVI infective endocarditis patients according to 2 studies. The surgical intervention and valve-in-valve procedure were reported in 11.4% and 6.4% cases, respectively.
The incidence of post-TAVI infective endocarditis is low being 3.25% but it is associated with high mortality and complications. The most common complication is heart failure with a cumulative incidence of 37.1%. Enterococciare the most common causative organism isolated from 25.9% of cases followed by Staphylococcus aureus in 16.1% of cases. Appropriate measures should be taken to prevent infective endocarditis in post-TAVI patients including adequate antibiotics prophylaxis directed specifically against these organisms.
PROSPERO registration number CRD42018115943.
经导管主动脉瓣置换术(TAVI)后感染性心内膜炎的数据稀缺,仅限于文献中的病例报告和病例系列。分析现有文献中 TAVI 后感染性心内膜炎的可用数据是当务之急。本系统评价的目的是评估经导管主动脉瓣置换术后感染性心内膜炎的发生率、其微生物谱和临床结局。这将有助于我们改进 TAVI 背景下感染性心内膜炎的抗生素预防策略和治疗选择。
EMBASE、Medline 和 Cochrane 协作中心临床试验注册库对截至 2018 年 10 月的 TAVI 后感染性心内膜炎患者的文章进行了检索。11 篇文章被纳入系统评价。评估的结果是感染性心内膜炎的发生率、微生物谱和临床结局,包括主要不良心脏事件(MACE)、净不良临床事件(NACE)、手术干预和瓣膜内瓣手术。
纳入研究中感染性心内膜炎的发生率为 0%-14.3%,平均为 3.25%。平均随访时间为 474 天(1.3 年)。粪肠球菌是最常见的致病微生物,占 25.9%,其次是金黄色葡萄球菌(16.1%)和凝固酶阴性葡萄球菌(14.7%)。住院死亡率和随访时死亡率分别为 29.5%和 29.9%。心力衰竭、中风和大出血的累积发生率分别为 37.1%、5.3%和 11.3%。仅 Martinez-Selles 等人的一项研究报告了 20%的心律失常病例。根据两项研究,10%和 27.7%的 TAVI 后感染性心内膜炎患者发生感染性休克。11.4%和 6.4%的患者分别报告了手术干预和瓣膜内瓣手术。
TAVI 后感染性心内膜炎的发生率较低(3.25%),但死亡率和并发症发生率高。最常见的并发症是心力衰竭,累积发生率为 37.1%。粪肠球菌是最常见的致病微生物,占 25.9%,其次是金黄色葡萄球菌,占 16.1%。应采取适当措施预防 TAVI 后患者发生感染性心内膜炎,包括针对这些微生物的适当抗生素预防。
PROSPERO 注册号 CRD42018115943。